Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      AMEDISYS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES 2023 GUIDANCE

      Amedisys Logo

      News provided by

      Amedisys, Inc.

      May 03, 2023, 16:31 ET

      Share this article

      Share this article


      BATON ROUGE, La., May 3, 2023 /PRNewswire/ -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2023.

      Three-Month Periods Ended March 31, 2023 and 2022

      • Net service revenue increased $11.1 million to $556.4 million compared to $545.3 million in 2022.
      • Net income attributable to Amedisys, Inc. of $25.2 million compared to $31.7 million in 2022.
      • Net income attributable to Amedisys, Inc. per diluted share of $0.77 compared to $0.97 in 2022.

      Adjusted Quarterly Results*

      • Adjusted EBITDA of $57.8 million compared to $66.3 million in 2022.
      • Adjusted net income attributable to Amedisys, Inc. of $32.7 million compared to $40.1 million in 2022.
      • Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.00 compared to $1.23 in 2022.

      * See pages 2 and 12 - 13 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.

      Richard Ashworth, President and Chief Executive Officer, stated, "I am very pleased by our strong outperformance on adjusted EBITDA and EPS versus our internal expectations this quarter, and I am incredibly thankful for our 18,000 associates who helped to deliver these results. Quality is a core value at Amedisys, and it was one of the biggest drivers for me in joining the organization. In my first few weeks here, I have had the distinct pleasure of spending time in the field with our caregivers and regional associates, and having the opportunity to see and hear all they do, it is no wonder why we are the highest quality provider in our spaces. Quality is also a self-fulfilling prophecy as higher quality drives better growth and financial performance. I look forward to our continued progress across our four strategic focus areas of Growth, People, Clinical Optimization and Contessa and am excited to deliver more quarters of repeatable and predictable financial performance."

      Scott Ginn, Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer, said, "I am very encouraged by our first quarter performance as our strong home health admissions and hospice adjusted EBITDA margin improvement outpaced our internal projections. We are on track in our clinical optimization initiatives which benefited the hospice segment in the first quarter but will ultimately benefit all segments as we eliminate administrative processes in our care centers in order to have a singular focus on patient care." 

      Updated 2023 Guidance

      We are updating our previously issued guidance:

      • Adjusted net service revenue is anticipated to be in the range of $2.254 billion to $2.274 billion.
      • Adjusted EBITDA is anticipated to be in the range of $235 million to $245 million.
      • Adjusted diluted earnings per share is anticipated to be in the range of $4.14 to $4.36 based on an estimated 32.8 million shares outstanding.

      This guidance excludes the effects of any future acquisitions and potential share repurchases, if any are made.

      The foregoing full year 2023 financial guidance excludes the impact of the Company's pending combination with Option Care Health.

      We urge caution in considering the current trends and 2023 guidance disclosed in this press release. The home health, hospice and high acuity care industries are highly competitive and subject to intensive regulations, and trends are subject to numerous factors, risks, and uncertainties, some of which are referenced in the cautionary language below and others that are described more fully in our reports filed with the Securities and Exchange Commission ("SEC") including our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K which can be found on the SEC's internet website, http://www.sec.gov, and our internet website, http://www.amedisys.com. 

      Earnings Call Information

      In a separate press release issued today, Amedisys announced it has entered into a definitive agreement to combine with Option Care Health.

      Amedisys and Option Care Health will host an investor call today at 5:30 p.m. Eastern Time to discuss the details of the transaction. Details for such call are available in the separate press release issued today. In light of the transaction announcement, we will forego our previously scheduled first quarter 2023 earnings conference call.

      Non-GAAP Financial Measures

      This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. ("GAAP") to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items; (2) adjusted net income attributable to Amedisys, Inc., defined as net income attributable to Amedisys, Inc. excluding certain items; and (3) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income attributable to Amedisys, Inc. common stockholders per diluted share excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to the GAAP financial measures presented in this earnings release and the company's financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.

      Additional Information

      Amedisys, Inc. (the "Company") is a leading healthcare at home company delivering personalized home health, hospice and high acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is in-patient hospital, palliative and skilled nursing facility ("SNF") care in their homes; home-based recovery and rehabilitation after an operation or injury, care focused on empowering our patients to manage a chronic disease, or hospice care at the end of life. More than 3,000 hospitals and 102,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 18,000 employees in 522 care centers within 37 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 455,000 patients and clients in need every year. For more information about the Company, please visit: www.amedisys.com.

      We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled "Investors" on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.

      Forward-Looking Statements

      When included in this press release, words like "believes," "belief," "expects," "strategy," "plans," "anticipates," "intends," "projects," "estimates," "may," "might," "will," "could," "would," "should" and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to, the following: the risk that the cost savings and any revenue synergies or other synergies from the proposed merger with Option Care Health may not be realized or may take longer than anticipated to be realized; disruption from the proposed merger with patient, payer, provider, referral sources, supplier or management and employee relationships; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement with Option Care Health or the inability to complete the proposed transaction on the anticipated terms and timetable; the risk that  necessary regulatory approvals for the proposed merger with Option Care Health are delayed, are not obtained or are obtained subject to conditions that are not anticipated; the failure of the conditions to the proposed merger to be satisfied; the inability to complete the proposed transaction due to the failure to obtain approval of the stockholders at Option Care Health or Amedisys or to satisfy any other condition in a timely manner or at all; the risks related to the integration of the combined businesses, including the risk that the integration will be materially delayed or will be more costly or difficult than expected; the ability of the combined company to execute carefully its strategic plans; the costs related to the proposed transaction; the diversion of management time on merger-related issues; the ability of Option Care Health to effectively manage the larger and more complex operations of the combined company following the proposed merger with the Company; reputational risk related to the proposed merger; the risk of litigation or regulatory action related to the proposed merger; changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients and payment methodologies; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; the impact of the novel coronavirus pandemic ("COVID-19") on our business, financial condition and results of operations; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

      Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

      Contact:

      Investor Contact:

      Media Contact:                                  


      Amedisys, Inc.

      Amedisys, Inc.


      Nick Muscato

      Kendra Kimmons


      Chief Strategy Officer

      Vice President, Marketing & Communications


      (615) 928- 5452

      (225) 299-3720


      [email protected]

      [email protected]

      AMEDISYS, INC. AND SUBSIDIARIES

      CONDENSED CONSOLIDATED INCOME STATEMENTS

      (Amounts in thousands, except per share data)

      (Unaudited)



      For the Three-Month 

      Periods Ended March 31,


      2023


      2022

      Net service revenue

      $         556,389


      $         545,257

      Operating expenses:




      Cost of service, inclusive of depreciation

      315,010


      304,820

      General and administrative expenses:




      Salaries and benefits

      126,339


      123,480

      Non-cash compensation

      3,273


      7,347

      Depreciation and amortization

      4,443


      8,008

      Other

      64,945


      53,640

      Total operating expenses

      514,010


      497,295

      Operating income

      42,379


      47,962

      Other income (expense):




      Interest income

      406


      13

      Interest expense

      (7,517)


      (3,173)

      Equity in earnings (loss) from equity method investments

      123


      (1,403)

      Miscellaneous, net

      (682)


      333

      Total other expense, net

      (7,670)


      (4,230)

      Income before income taxes

      34,709


      43,732

      Income tax expense

      (9,800)


      (12,019)

      Net income

      24,909


      31,713

      Net loss (income) attributable to noncontrolling interests

      337


      (42)

      Net income attributable to Amedisys, Inc.

      $           25,246


      $           31,671

      Basic earnings per common share:




      Net income attributable to Amedisys, Inc. common stockholders

      $                0.78


      $                0.97

      Weighted average shares outstanding

      32,558


      32,555

      Diluted earnings per common share:




      Net income attributable to Amedisys, Inc. common stockholders

      $                0.77


      $                0.97

      Weighted average shares outstanding

      32,643


      32,766

      AMEDISYS, INC. AND SUBSIDIARIES

      CONDENSED CONSOLIDATED BALANCE SHEETS

      (Amounts in thousands, except share data)



      March 31, 2023
      (unaudited)


      December 31,
      2022

      ASSETS




      Current assets:




      Cash and cash equivalents

      $           49,436


      $           40,540

      Restricted cash

      19,664


      13,593

      Patient accounts receivable

      294,122


      296,785

      Prepaid expenses

      18,754


      11,628

      Other current assets

      23,581


      26,415

      Total current assets

      405,557


      388,961

      Property and equipment, net of accumulated depreciation of $105,183 and $101,364

      33,353


      16,026

      Operating lease right of use assets

      85,211


      102,856

      Goodwill

      1,244,679


      1,287,399

      Intangible assets, net of accumulated amortization of $16,071 and $14,604

      99,929


      101,167

      Other assets

      78,230


      79,836

      Total assets

      $      1,946,959


      $      1,976,245

      LIABILITIES AND EQUITY




      Current liabilities:




      Accounts payable

      $           40,017


      $           43,735

      Payroll and employee benefits

      122,723


      125,387

      Accrued expenses

      137,899


      137,390

      Current portion of long-term obligations

      26,958


      15,496

      Current portion of operating lease liabilities

      25,453


      33,521

      Total current liabilities

      353,050


      355,529

      Long-term obligations, less current portion

      373,202


      419,420

      Operating lease liabilities, less current portion

      59,826


      69,504

      Deferred income tax liabilities

      22,752


      20,411

      Other long-term obligations

      4,781


      4,808

      Total liabilities

      813,611


      869,672

      Equity:




      Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding

      —


      —

      Common stock, $0.001 par value, 60,000,000 shares authorized; 37,938,354 and 37,891,186 shares issued; 32,544,145 and 32,511,465 shares outstanding

      38


      38

      Additional paid-in capital

      758,669


      755,063

      Treasury stock, at cost, 5,394,209 and 5,379,721 shares of common stock

      (462,508)


      (461,200)

      Retained earnings

      782,918


      757,672

      Total Amedisys, Inc. stockholders' equity

      1,079,117


      1,051,573

      Noncontrolling interests

      54,231


      55,000

      Total equity

      1,133,348


      1,106,573

      Total liabilities and equity

      $      1,946,959


      $      1,976,245

      AMEDISYS, INC. AND SUBSIDIARIES

      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING

      (Amounts in thousands, except statistical information)

      (Unaudited)



      For the Three-Month

      Periods Ended March 31,


      2023


      2022

      Cash Flows from Operating Activities:




      Net income

      $      24,909


      $      31,713

      Adjustments to reconcile net income to net cash provided by operating activities:




      Depreciation and amortization (inclusive of depreciation included in cost of service)

      5,694


      8,008

      Non-cash compensation

      3,273


      7,347

      Amortization and impairment of operating lease right of use assets

      8,622


      10,096

      (Gain) loss on disposal of property and equipment

      (70)


      5

      Loss on personal care divestiture

      2,186


      —

      Deferred income taxes

      2,772


      3,205

      Equity in (earnings) loss from equity method investments

      (123)


      1,403

      Amortization of deferred debt issuance costs

      248


      248

      Return on equity method investments

      1,787


      1,710

      Changes in operating assets and liabilities, net of impact of acquisitions:




      Patient accounts receivable

      (7,476)


      (18,618)

      Other current assets

      (4,128)


      7,882

      Operating lease right of use assets

      (918)


      (749)

      Other assets

      (111)


      247

      Accounts payable

      (3,457)


      (2,115)

      Accrued expenses

      741


      7,483

      Other long-term obligations

      (28)


      (57)

      Operating lease liabilities

      (7,960)


      (9,187)

      Net cash provided by operating activities

      25,961


      48,621

      Cash Flows from Investing Activities:




      Proceeds from the sale of deferred compensation plan assets

      19


      22

      Proceeds from the sale of property and equipment

      —


      37

      Purchases of property and equipment

      (1,350)


      (902)

      Investments in technology assets

      (210)


      (236)

      Purchase of cost method investment

      —


      (15,000)

      Proceeds from personal care divestiture

      47,787


      —

      Acquisitions of businesses, net of cash acquired

      (350)


      —

      Net cash provided by (used in) investing activities

      45,896


      (16,079)

      Cash Flows from Financing Activities:




      Proceeds from issuance of stock upon exercise of stock options

      —


      86

      Proceeds from issuance of stock to employee stock purchase plan

      816


      985

      Shares withheld to pay taxes on non-cash compensation

      (1,308)


      (4,682)

      Noncontrolling interest contributions

      —


      652

      Noncontrolling interest distributions

      (285)


      (672)

      Proceeds from borrowings under revolving line of credit

      8,000


      —

      Repayments of borrowings under revolving line of credit

      (8,000)


      —

      Principal payments of long-term obligations

      (55,313)


      (3,771)

      Purchase of noncontrolling interest

      (800)


      —

      Net cash used in financing activities

      (56,890)


      (7,402)

      Net increase in cash, cash equivalents and restricted cash

      14,967


      25,140

      Cash, cash equivalents and restricted cash at beginning of period

      54,133


      45,769

      Cash, cash equivalents and restricted cash at end of period

      $      69,100


      $      70,909






      For the Three-Month 

      Periods Ended March 31,


      2023


      2022

      Supplemental Disclosures of Cash Flow Information:




      Cash paid for interest

      $        6,654


      $        1,864

      Cash paid for income taxes, net of refunds received

      $           352


      $            551

      Cash paid for operating lease liabilities

      $        8,878


      $        9,936

      Cash paid for finance lease liabilities

      $        2,457


      $            357

      Supplemental Disclosures of Non-Cash Activity:




      Right of use assets obtained in exchange for operating lease liabilities

      $        7,083


      $      11,203

      Right of use assets obtained in exchange for finance lease liabilities

      $      20,790


      $            216

      Reductions to right of use assets resulting from reductions to operating lease liabilities

      $           141


      $            299

      Reductions to right of use assets resulting from reductions to finance lease liabilities

      $           369


      $              —

      Noncontrolling interest contribution

      $              —


      $        8,900

      Days revenue outstanding (1)

      46.3


      46.3

      (1)

      Our calculation of days revenue outstanding at March 31, 2023 and 2022 is derived by dividing our ending patient accounts receivable by our average daily patient revenue for the three-month periods ended March 31, 2023 and 2022, respectively.

      AMEDISYS, INC. AND SUBSIDIARIES

      SEGMENT INFORMATION

      (Amounts in millions, except statistical information)

      (Unaudited)


      Segment Information - Home Health



      For the Three-Month Periods

      Ended March 31,


      2023


      2022

      Financial Information (in millions) (6):




      Medicare

      $        215.4


      $        224.1

      Non-Medicare

      127.9


      111.6

      Net service revenue

      343.3


      335.7

      Cost of service, inclusive of depreciation

      197.0


      185.2

      Gross margin

      146.3


      150.5

      General and administrative expenses

      89.1


      83.2

      Depreciation and amortization

      1.1


      0.9

      Operating income

      $          56.1


      $          66.4

      Same Store Growth(1):




      Medicare revenue

      (7 %)


      1 %

      Non-Medicare revenue

      12 %


      4 %

      Total admissions

      8 %


      2 %

      Total volume(2)

      5 %


      — %

      Key Statistical Data - Total(3)(6):




      Admissions

      101,963


      91,764

      Recertifications

      43,325


      42,856

      Total volume

      145,288


      134,620





      Medicare completed episodes

      73,563


      74,443

      Average Medicare revenue per completed episode(4)

      $        2,974


      $        3,013

      Medicare visits per completed episode(5)

      12.4


      13.0





      Visiting clinician cost per visit

      $     100.00


      $        97.28

      Clinical manager cost per visit

      10.97


      10.62

      Total cost per visit

      $     110.97


      $     107.90

      Visits

      1,775,206


      1,716,211

      (1)

      Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.

      (2)

      Total volume includes all admissions and recertifications.

      (3)

      Total includes acquisitions, start-ups and denovos.

      (4)

      Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the suspension of sequestration for the three-month period ended March 31, 2022 and the reinstatement of sequestration at 2% for the three-month period ended March 31, 2023.

      (5)

      Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.

      (6)

      Prior year has been recast to conform to the current year presentation.

      Segment Information - Hospice



      For the Three-Month Periods

      Ended March 31,


      2023


      2022

      Financial Information (in millions):




      Medicare

      $        182.7


      $        182.5

      Non-Medicare

      10.7


      10.6

      Net service revenue

      193.4


      193.1

      Cost of service, inclusive of depreciation

      101.4


      106.4

      Gross margin

      92.0


      86.7

      General and administrative expenses

      47.9


      51.3

      Depreciation and amortization

      0.6


      0.6

      Operating income

      $          43.5


      $          34.8

      Same Store Growth(1):




      Medicare revenue

      — %


      1 %

      Hospice admissions

      (5 %)


      2 %

      Average daily census

      (1 %)


      (3 %)

      Key Statistical Data - Total(2):




      Hospice admissions

      12,998


      13,886

      Average daily census

      12,730


      12,920

      Revenue per day, net

      $     168.83


      $     166.04

      Cost of service per day

      $        88.21


      $        91.48

      Average discharge length of stay

      90


      89

      (1)

      Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.

      (2)

      Total includes acquisitions and denovos.

      Segment Information - Personal Care (1)



      For the Three-Month Periods

      Ended March 31,


      2023


      2022

      Financial Information (in millions):




      Medicare

      $                 —


      $                 —

      Non-Medicare

      15.0


      14.0

      Net service revenue

      15.0


      14.0

      Cost of service, inclusive of depreciation

      11.1


      10.8

      Gross margin

      3.9


      3.2

      General and administrative expenses

      2.3


      2.2

      Depreciation and amortization

      —


      0.1

      Operating income

      $                1.6


      $                0.9

      Key Statistical Data - Total:




      Billable hours

      440,464


      451,032

      Clients served

      7,892


      7,479

      Shifts

      191,379


      193,742

      Revenue per hour

      $           33.97


      $           30.95

      Revenue per shift

      $           78.19


      $           72.04

      Hours per shift

      2.3


      2.3

      (1)

      We completed the sale of our personal care business on March 31, 2023.

      Segment Information - High Acuity Care



      For the Three-Month Periods

      Ended March 31,


      2023


      2022

      Financial Information (in millions) (1):




      Medicare

      $                 —


      $                 —

      Non-Medicare

      4.7


      2.5

      Net service revenue

      4.7


      2.5

      Cost of service, inclusive of depreciation

      5.5


      2.4

      Gross margin

      (0.8)


      0.1

      General and administrative expenses

      4.4


      4.3

      Depreciation and amortization

      0.8


      0.8

      Operating loss

      $              (6.0)


      $              (5.0)

      Key Statistical Data - Total:




      Full risk admissions

      158


      106

      Limited risk admissions

      459


      227

      Total admissions

      617


      333





      Full risk revenue per episode

      $         11,343


      $         10,077

      Limited risk revenue per episode

      $           5,711


      $           5,779





      Number of admitting joint venture markets

      10


      9

      (1)

      Prior year has been recast to conform to the current year presentation.

      Segment Information - Corporate



      For the Three-Month Periods

      Ended March 31,


      2023


      2022

      Financial Information (in millions) (1):




      General and administrative expenses

      $              50.9


      $              43.5

      Depreciation and amortization

      1.9


      5.6

      Total operating expenses

      $              52.8


      $              49.1

      (1)

      Prior year has been recast to conform to the current year presentation.

      AMEDISYS, INC. AND SUBSIDIARIES

      RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES

      (Amounts in thousands)

      (Unaudited)


      Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA") Reconciliation:



      For the Three-Month Periods

      Ended March 31,


      2023


      2022

      Net income attributable to Amedisys, Inc.

      $      25,246


      $      31,671

      Add:




              Income tax expense

      9,800


      12,019

              Interest expense, net

      7,111


      3,160

              Depreciation and amortization

      5,694


      8,008

              Certain items(1)

      9,987


      11,450

      Adjusted EBITDA(2)(5)

      $      57,838


      $      66,308



      Adjusted Net Income Attributable to Amedisys, Inc Reconciliation:



      For the Three-Month Periods

      Ended March 31,


      2023


      2022

      Net income attributable to Amedisys, Inc.

      $      25,246


      $      31,671

      Add:




              Certain items(1)

      7,489


      8,473

      Adjusted net income attributable to Amedisys, Inc.(3)(5)

      $      32,735


      $      40,144



      Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation:



      For the Three-Month Periods

      Ended March 31,


      2023


      2022

      Net income attributable to Amedisys, Inc. common stockholders per diluted share

      $          0.77


      $          0.97

      Add:




              Certain items(1)

      0.23


      0.26

      Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share(4)(5)

      $          1.00


      $          1.23

      (1)

      The following details the certain items for the three-month periods ended March 31, 2023 and 2022:

      Certain Items:



      For the Three-Month Periods

      Ended March 31,


      2023


      2022


      (Income) Expense


      (Income) Expense

      Certain Items Impacting Cost of Service, Inclusive of Depreciation:




      COVID-19 costs

      $                                      —


      $                                  3,733

      Fuel supplement

      —


      337

      Clinical optimization and reorganization costs

      114


      —

      Certain Items Impacting General and Administrative Expenses:




      Acquisition and integration costs

      1,667


      1,378

      COVID-19 costs

      —


      153

      Executive Board of Directors/CEO transition award

      750


      3,500

      Legal fees - non-routine

      —


      51

      Clinical optimization and reorganization costs

      3,890


      —

      Personal care divestiture

      514


      —

      Certain Items Impacting Total Other Income (Expense):




      Other (income) expense, net

      3,052


      2,298

      Total

      $                                9,987


      $                                11,450

      Net of tax

      $                                7,489


      $                                  8,473

      Diluted EPS

      $                                   0.23


      $                                    0.26

      (2)

      Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as described in footnote 1.

      (3)

      Adjusted net income attributable to Amedisys, Inc. is defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.

      (4)

      Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.

      (5)

      Adjusted EBITDA, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.

      SOURCE Amedisys, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.